» Articles » PMID: 30310466

Nicorandil and Long-acting Nitrates: Vasodilator Therapies for the Management of Chronic Stable Angina Pectoris

Overview
Journal Eur Cardiol
Date 2018 Oct 13
PMID 30310466
Citations 24
Authors
Affiliations
Soon will be listed here.
Abstract

Nicorandil and long-acting nitrates are vasodilatory drugs used commonly in the management of chronic stable angina pectoris. Both nicorandil and long-acting nitrates exert anti-angina properties via activation of nitric oxide (NO) signalling pathways, triggering vascular smooth muscle cell relaxation. Nicorandil has additional actions as an arterial K channel agonist, resulting in more "balanced" arterial and venous vasodilatation than nitrates. Ultimately, these drugs prevent angina symptoms through reductions in preload and diastolic wall tension and, to a lesser extent, epicardial coronary artery dilatation and lowering of systemic blood pressure. While there is some evidence to suggest a modest reduction in cardiovascular events among patients with stable angina treated with nicorandil compared to placebo, this prognostic benefit has yet to be proven conclusively. In contrast, there is emerging evidence to suggest that chronic use of long-acting nitrates might cause endothelial dysfunction and increased cardiovascular risk in some patients.

Citing Articles

Preventive effects of nitric oxide donors in contrast-induced nephropathy in patients undergoing coronary artery angiography: an updated systematic review and meta-analysis of 13 randomized controlled trials.

Ibrahim A, Tabassum S, Abuelazm M, Amin A, Rakab M, Rifai M Int Urol Nephrol. 2024; 57(4):1207-1232.

PMID: 39548033 DOI: 10.1007/s11255-024-04261-9.


Nicorandil antiallodynic activity in a model of neuropathic pain is associated with the activation of ATP-dependent potassium channels and opioidergic pathways, and reduced production of cytokines and neutrophils recruitment in paw, sciatic nerve,....

Braga A, Morais M, Delfino D, Costa S, Barbosa B, Rodrigues F Pharmacol Rep. 2024; 76(5):1067-1078.

PMID: 39179890 DOI: 10.1007/s43440-024-00640-2.


Mechanism of action and neuroprotective role of nicorandil in ischemic stroke.

Owjfard M, Rahmani N, Mallahzadeh A, Bayat M, Borhani-Haghighi A, Karimi F Heliyon. 2024; 10(4):e26640.

PMID: 38434007 PMC: 10906150. DOI: 10.1016/j.heliyon.2024.e26640.


Coronary spasm and vasomotor dysfunction as a cause of MINOCA.

Yaker Z, Lincoff A, Cho L, Ellis S, Ziada K, Zieminski J EuroIntervention. 2024; 20(2):e123-e134.

PMID: 38224252 PMC: 10786177. DOI: 10.4244/EIJ-D-23-00448.


Management of Coronary Artery Spasm.

Lanza G, Shimokawa H Eur Cardiol. 2023; 18:e38.

PMID: 37456765 PMC: 10345953. DOI: 10.15420/ecr.2022.47.


References
1.
DORING G . Antianginal and anti-ischemic efficacy of nicorandil in comparison with isosorbide-5-mononitrate and isosorbide dinitrate: results from two multicenter, double-blind, randomized studies with stable coronary heart disease patients. J Cardiovasc Pharmacol. 1992; 20 Suppl 3:S74-81. View

2.
. Effect of nicorandil on coronary events in patients with stable angina: the Impact Of Nicorandil in Angina (IONA) randomised trial. Lancet. 2002; 359(9314):1269-75. DOI: 10.1016/S0140-6736(02)08265-X. View

3.
Rajaratnam R, Brieger D, Hawkins R, Freedman S . Attenuation of anti-ischemic efficacy during chronic therapy with nicorandil in patients with stable angina pectoris. Am J Cardiol. 1999; 83(7):1120-4, A9. DOI: 10.1016/s0002-9149(99)00025-9. View

4.
Hayata N, Araki H, Nakamura M . Effects of nicorandil on exercise tolerance in patients with stable effort angina: a double-blind study. Am Heart J. 1986; 112(6):1245-50. DOI: 10.1016/0002-8703(86)90355-8. View

5.
Why H, Richardson P . A potassium channel opener as monotherapy in chronic stable angina pectoris: comparison with placebo. Eur Heart J. 1993; 14 Suppl B:25-9. DOI: 10.1093/eurheartj/14.suppl_b.25. View